다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Multiple sclerosis journal: clinical and laboratory research, v.24 no.7, 2018년, pp.919 - 931
Redondo, Juliana (School of Clinical Sciences, University of Bristol, Bristol, UK) , Sarkar, Pamela (School of Clinical Sciences, University of Bristol, Bristol, UK) , Kemp, Kevin (School of Clinical Sciences, University of Bristol, Bristol, UK) , Virgo, Paul F (Department of Immunology, Southmead Hospital, Bristol, UK) , Pawade, Joya (Department of Pathology, Southmead Hospital, Bristol, UK) , Norton, Aimie (Department of Pathology, Southmead Hospital, Bristol, UK) , Emery, David C (School of Clinical Sciences, University of Bristol, Bristol, UK) , Guttridge, Martin G (NHS Blood and Transplant, Bristol, UK) , Marks, David I (Blood and Marrow Transplant Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, UK) , Wilkins, Alastair (School of Clinical Sciences, University of Bristol, Bristol, UK) , Scolding, Neil J (School of Clinical Sciences, University of Bristol, Bristol, UK) , Rice, Claire M (School of Clinical Sciences, University of Bristol, Bristol, UK)
AI-Helper
Background:Autologous bone-marrow-derived cells are currently employed in clinical studies of cell-based therapy in multiple sclerosis (MS) although the bone marrow microenvironment and marrow-derived cells isolated from patients with MS have not been extensively characterised.Objectives:To examine ...
1 Rice CM Kemp K Wilkins A et al Cell therapy for multiple sclerosis: An evolving concept with implications for other neurodegenerative diseases . Lancet 2013 ; 382 ( 9899 ): 1204 – 1213 . 24095194
2 Carrai V Donnini I Mazzanti B et al Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation . Clin Neurol Neurosurg 2013 ; 115 : 1044 – 1048 . 23218837
3 Papadaki HA Tsagournisakis M Mastorodemos V et al Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis . Bone Marrow Transplant 2005 ; 36 : 1053 – 1063 . 16205726
4 Mazzanti B Aldinucci A Biagioli T et al Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment . J Neuroimmunol 2008 ; 199 : 142 – 150 . 18562015
5 Mallam E Kemp K Wilkins A et al Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis . Mult Scler 2010 ; 16 : 909 – 918 . 20542920
6 Harris VK Faroqui R Vyshkina T et al Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis . Stem Cells Transl Med 2012 ; 1 : 536 – 547 . 23197858
7 De Oliveira GL De Lima KW Colombini AM et al Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts . Cell Transplant 2015 ; 24 : 151 – 165 . 24256874
8 Wang J Liao L Wang S et al Cell therapy with autologous mesenchymal stem cells-how the disease process impacts clinical considerations . Cytotherapy 2013 ; 15 : 893 – 904 . 23751203
9 Jons D Kneider M Fogelstrand L et al Early hematopoiesis in multiple sclerosis patients . J Neuroimmunol 2016 ; 299 : 158 – 163 . 27725115
10 Rice CM Marks DI Walsh P et al Repeat infusion of autologous bone marrow cells in multiple sclerosis: Protocol for a phase I extension study (SIAMMS-II) . BMJ Open 2015 ; 5 : e009090 .
11 Rice CM Marks DI Ben-Shlomo Y et al Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): Study protocol for a randomised controlled trial . Trials 2015 ; 16 : 463 . 26467901
12 Guttridge MG Belfield H Hollyman D et al An internal positive control for the enumeration of CD45(+) and CD34(+) cells by flow cytometry allows monitoring of reagent and operator performance . Cytotherapy 2007 ; 9 : 275 – 282 . 17464759
13 Kemp K Hares K Mallam E et al Mesenchymal stem cell-secreted superoxide dismutase promotes cerebellar neuronal survival . J Neurochem 2010 ; 114 : 1569 – 1580 . 20028455
14 Dominici M Le Blanc K Mueller I et al Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement . Cytotherapy 2006 ; 8 : 315 – 317 . 16923606
15 Orazi A O’Malley D Arber D. Illustrated pathology of the bone marrow . Cambridge : Cambridge University Press , 2006 .
16 Kresnik PK Krasna M Rozman P et al Collection and immunoselection of CD34+ cells: The impact of age, sex, and diabetes in patients with chronic heart failure . Transfusion 2016 ; 56 : 1792 – 1800 . 27185200
17 Wagner W Horn P Castoldi M et al Replicative senescence of mesenchymal stem cells: A continuous and organized process . PLoS ONE 2008 ; 3 : e2213 . 18493317
18 Simmons PJ Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1 . Blood 1991 ; 78 : 55 – 62 . 2070060
19 Uccelli A Laroni A Freedman MS. Mesenchymal stem cells as treatment for MS – Progress to date . Mult Scler 2013 ; 19 : 515 – 519 . 23124791
20 Fredrikson S Baig S Link H. Immunoglobulin producing cells in bone marrow and blood of patients with multiple sclerosis and controls . J Neurol Neurosurg Psychiatry 1991 ; 54 : 412 – 414 . 1713951
21 Guan JZ Guan WP Maeda T et al Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening . Mol Cell Biochem 2015 ; 400 : 183 – 187 . 25424527
22 Stolzing A Jones E McGonagle D et al Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies . Mech Ageing Dev 2008 ; 129 : 163 – 173 . 18241911
23 Beane OS Fonseca VC Cooper LL et al Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells . PLoS ONE 2014 ; 9 : e115963 . 25541697
24 Von Bahr L Sundberg B Lonnies L et al Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy . Biol Blood Marrow Transplant 2012 ; 18 : 557 – 564 . 21820393
25 Scalfari A Neuhaus A Degenhardt A et al The natural history of multiple sclerosis, a geographically based study 10: Relapses and long-term disability . Brain 2010 ; 133 : 1914 – 1929 . 20534650
26 Tutuncu M Tang J Zeid NA et al Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis . Mult Scler 2013 ; 19 : 188 – 198 . 22736750
27 Minden SL Frankel D Hadden LS et al Disability in elderly people with multiple sclerosis: An analysis of baseline data from the Sonya Slifka Longitudinal Multiple Sclerosis Study . NeuroRehabilitation 2004 ; 19 : 55 – 67 . 14988588
28 Scalfari A Neuhaus A Daumer M et al Age and disability accumulation in multiple sclerosis . Neurology 2011 ; 77 : 1246 – 1252 . 21917763
29 Sim FJ Zhao C Penderis J et al The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation . J Neurosci 2002 ; 22 : 2451 – 2459 . 11923409
30 Larochelle C Uphaus T Prat A et al Secondary progression in multiple sclerosis: Neuronal exhaustion or distinct pathology? Trends Neurosci 2016 ; 39 : 325 – 339 . 26987259
31 Lopez-Otin C Blasco MA Partridge L et al The hallmarks of aging . Cell 2013 ; 153 : 1194 – 1217 . 23746838
32 Confavreux C Vukusic S. Age at disability milestones in multiple sclerosis . Brain 2006 ; 129 : 595 – 605 . 16415309
33 Coles AJ Cox A Le Page E et al The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy . J Neurol 2006 ; 253 : 98 – 108 . 16044212
34 Davies BM Snelling SJ Quek L et al Identifying the optimum source of mesenchymal stem cells for use in knee surgery . J Orthop Res . Epub ahead of print 9 12 2016 DOI: 10.1002/jor.23501.
35 Narbona-Carceles J Vaquero J Suarez-Sancho S et al Bone marrow mesenchymal stem cell aspirates from alternative sources: Is the knee as good as the iliac crest? Injury 2014 ; 45 ( suppl. 4 ): S42 – S47 . 25384474
36 Hyer CF Berlet GC Bussewitz BW et al Quantitative assessment of the yield of osteoblastic connective tissue progenitors in bone marrow aspirate from the iliac crest, tibia, and calcaneus . J Bone Joint Surg Am 2013 ; 95 : 1312 – 1316 . 23864180
37 Garcia-Alvarez F Alegre-Aguaron E Desportes P et al Chondrogenic differentiation in femoral bone marrow-derived mesenchymal cells (MSC) from elderly patients suffering osteoarthritis or femoral fracture . Arch Gerontol Geriatr 2011 ; 52 : 239 – 242 . 20416958
38 Jones E English A Churchman SM et al Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: Implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells . Arthritis Rheum 2010 ; 62 : 1944 – 1954 . 20222109
39 Scharstuhl A Schewe B Benz K et al Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology . Stem Cells 2007 ; 25 : 3244 – 3251 . 17872501
40 Murphy JM Dixon K Beck S et al Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis . Arthritis Rheum 2002 ; 46 : 704 – 713 . 11920406
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.